Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia

Daniela Asslaber, Josefina D. Piñón, Irina Seyfried, Petra Desch, Markus Stöcher, Inge Tinhofer, Alexander Egle, Olaf Merkel, Richard Greil

Blood (2010) 115 (21): 4191–4197.

https://doi.org/10.1182/blood-2009-07-234823

Published: 2010

Journal Articles

The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia.

Lukas Weiss, MD, Thomas Melchardt, MD, Christoph Grabmer, MD, Alexander Egle, MD, Inge Tinhofer, PhD, Richard Greil, MD

Blood (2009) 114 (22): 1238.

https://doi.org/10.1182/blood.V114.22.1238.1238

Published: 2009

Journal Articles

Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories

Michael Fiegl, Martin Erdel, Inge Tinhofer, Georg Hopfinger, Karin Eigenberger, Florian Falkner, Andreas Falkner, Yvona Brychtova, Anna Panovska, Michael Doubek, August Zabernigg, Sigrun Sodia, Helmut Mühlberger, Christa Fonatsch, Günther Gastl, Jiri Mayer, Richard Greil

Blood (2008) 112 (11): 3164.

https://doi.org/10.1182/blood.V112.11.3164.3164

Published: 2008

Journal Articles

Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study

Alexander Egle, MD, Lukas Weiss, Franz Gassner, Gudrun Russ, Lisa Pleyer, Eberhard Gunsilius, MD, Inge Tinhofer, Josef Thaler, MD, Andreas L. Petzer, MD, Richard Greil

Blood (2008) 112 (11): 3175.

https://doi.org/10.1182/blood.V112.11.3175.3175

Published: 2008

Journal Articles

T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcl1 Transgenic Chronic Lymphocytic Leukemia Model

Alexander Egle, MD, Josefina D. Pinon, Christoph Heyder, Claudia Holler, Ursula Denk, Inge Tinhofer, PhD, Richard Greil

Blood (2008) 112 (11): 3145.

https://doi.org/10.1182/blood.V112.11.3145.3145

Published: 2008

Journal Articles

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

Irina Seyfried, Sebastian Hofbauer, Markus Stoecher, Richard Greil, Inge Tinhofer

Blood (2008) 112 (5): 2168.

https://doi.org/10.1182/blood-2008-05-158634

Published: 2008

Journal Articles

Planned First Efficacy and Safety Analysis of De-Intensified Induction with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos Study.

Alexander Egle, MD, Lukas Weiss, MD, Gudrun Russ, MD, Ralf Thoedtmann, MD, Lisa Pleyer, MD, Guenther Gastl, MD, Josef Thaler, MD, Andreas Petzer, MD, Inge Tinhofer, PhD, Richard Greil, MD

Blood (2007) 110 (11): 2045.

https://doi.org/10.1182/blood.V110.11.2045.2045

Published: 2007

Journal Articles

Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL.

Michael Fiegl, Florian Falkner, Andreas Falkner, Niklas Zojer, Michael Fridrik, Georg Hopfinger, Reinhard Stauder, Ebehard Gunsilius, Johanna Kantner, Martin Erdel, Inge Tinhofer, Guenther Gastl, Richard Greil, the Austrian Cooperation on MabCampath Use in CLL

Blood (2007) 110 (11): 4714.

https://doi.org/10.1182/blood.V110.11.4714.4714

Published: 2007

Journal Articles

Planned First Safety and Efficacy Analysis of Oral Fludarabine Combined with Subcutaneous Alemtuzumab in 2 nd Line Therapy of B-Chronic Lymphocytic Leukaemia (B-CLL): The FLUSALEM Study.

Alexander Egle, Inge Tinhofer, G. Russ, C. Rass, Richard Greil

Blood (2006) 108 (11): 4990.

https://doi.org/10.1182/blood.V108.11.4990.4990

Published: 2006

Journal Articles

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia

Inge Tinhofer, Gabriele Rubenzer, Claudia Holler, Elisabeth Hofstaetter, Markus Stoecher, Alexander Egle, Michael Steurer, Richard Greil

Blood (2006) 108 (9): 2950–2956.

https://doi.org/10.1182/blood-2006-03-010553

Published: 2006

Journal Articles

Expression Levels of CD38 in Tumor Cells and T-Cells Are of Prognostic Value in B-CLL.

Inge Tinhofer, PhD, Gabriele Rubenzer, Alexander Egle, MD, Richard Greil, MD

Blood (2005) 106 (11): 1189.

https://doi.org/10.1182/blood.V106.11.1189.1189

Published: 2005

Journal Articles

Tetrocarcin-A—induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2—independent pathway

Gabriele Anether, Inge Tinhofer, Monika Senfter, Richard Greil

Blood (2003) 101 (11): 4561–4568.

https://doi.org/10.1182/blood-2002-08-2501

Published: 2003

Journal Articles

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia

Gabriele Anether, Ingrid Marschitz, Inge Tinhofer, Richard Greil

Blood (2002) 99 (2): 722–723.

https://doi.org/10.1182/blood.V99.2.722

Published: 2002

Journal Articles

Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma

Inge Tinhofer, Ingrid Marschitz, Traudl Henn, Alexander Egle, Richard Greil

Blood (2000) 95 (2): 610–618.

https://doi.org/10.1182/blood.V95.2.610

Published: 2000

Journal Articles

Differential Sensitivity of CD4 + and CD8 + T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand + Tumor Cells in B Chronic Lymphocytic Leukemia

Inge Tinhofer, Ingrid Marschitz, Marion Kos, Traudl Henn, Alexander Egle, Andreas Villunger, Richard Greil

Blood (1998) 91 (11): 4273–4281.

https://doi.org/10.1182/blood.V91.11.4273

Published: 1998

NARROW

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia

The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia.

Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories

T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcl1 Transgenic Chronic Lymphocytic Leukemia Model

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

Retreatment with Alemtuzumab after a First, Successful Alemtuzumab Treatment in B-CLL.

Planned First Safety and Efficacy Analysis of Oral Fludarabine Combined with Subcutaneous Alemtuzumab in 2 nd Line Therapy of B-Chronic Lymphocytic Leukaemia (B-CLL): The FLUSALEM Study.

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia

Expression Levels of CD38 in Tumor Cells and T-Cells Are of Prognostic Value in B-CLL.

Tetrocarcin-A—induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2—independent pathway

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia

Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma

Differential Sensitivity of CD4 + and CD8 + T Lymphocytes to the Killing Efficacy of Fas (Apo-1/CD95) Ligand + Tumor Cells in B Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only